Related Experiment Video
Updated: Oct 5, 2025

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
Features of atherosclerosis in patients with angina and no obstructive coronary artery disease
Dario Pellegrini1,2, Regina Konst1, Stijn van den Oord1
1Radboud University Medical Center, Department of Cardiology, Nijmegen, the Netherlands.
Insights
Coronary vasospasm in patients with angina and no obstructive coronary artery disease is linked to increased lipid burden and plaque vulnerability. This finding highlights specific atherosclerotic features associated with coronary vasomotor dysfunction.
Area of Science:
- Cardiology
- Vascular Biology
- Medical Imaging
Background:
- Atherosclerosis and coronary vasospasm association suggested but not conclusively proven.
- Limited data exists on the full spectrum of these related cardiovascular disorders.
Purpose of the Study:
- Define specific atherosclerotic morphological features in patients with angina and no obstructive coronary artery disease (ANOCA).
- Investigate the link between coronary vasospasm and atherosclerosis characteristics in ANOCA patients.
Main Methods:
- Enrolled 75 ANOCA patients undergoing coronary function tests (CFT) including acetylcholine and adenosine challenges.
- Utilized optical coherence tomography (OCT) to assess lipid index (LI) and plaque vulnerability markers.
- Grouped patients based on acetylcholine-induced coronary vasospasm (ACH+ vs. ACH-).
Main Results:
- ACH+ patients exhibited significantly higher lipid index (LI) and prevalence of vulnerable plaques compared to ACH- patients.
- Neovascularization was more prevalent in ACH+ individuals (37% vs. 6%).
- A trend towards higher prevalence of vulnerable plaque markers, including thin-cap fibroatheroma, was observed in ACH+ patients.
Conclusions:
- Coronary vasospasm, irrespective of its pattern, correlates with increased lipid burden and plaque vulnerability.
- Findings suggest a significant association between coronary vasospasm and specific atherosclerotic features in ANOCA.
Background:
An association between atherosclerosis and coronary vasospasm has previously been suggested. However, to date, no conclusive data on the whole spectrum of these disorders have been published.
Aims:
This study aimed to define specific morphological features of atherosclerosis in patients with angina and no obstructive coronary artery disease (ANOCA) due to coronary vasospasm.
Methods:
From February 2019 to January 2020, we enrolled 75 patients referred to our laboratory for a coronary function test (CFT) due to ANOCA and suspected coronary vasomotor dysfunction. The CFT consisted of an acetylcholine test and a physiology assessment with hyperaemic indexes using adenosine. Patients were divided into two groups according to the presence or absence of coronary vasospasm triggered by acetylcholine (ACH+ and ACH-, respectively). In addition, optical coherence tomography (OCT) was performed to assess the lipid index (LI), a surrogate for lipid area, and the prevalence of markers of plaque vulnerability.
Results:
ACH+ patients had a higher LI than ACH- patients (LI: 819.85 [460.95-2489.03] vs 269.95 [243.50-878.05], respectively, p=0.03), and a higher prevalence of vulnerable plaques (66% vs 38%, p=0.04). Moreover, ACH+ patients showed a higher prevalence of neovascularisation compared to ACH- subjects (37% vs 6%, p=0.02) and a trend towards a higher prevalence of all individual markers, in particular thin-cap fibroatheroma (20% vs 0%, p=0.06). No differences were detected between patterns of coronary vasospasm.
Conclusions:
The presence of coronary vasospasm, regardless of its phenotype, is associated with higher lipid burden, plaque vulnerability and neovascularisation.
Related Concept Videos
Angina II: Classification
Angina III: Clinical Manifestations and Assessment
Angina I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations

